![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance Analysis in 1284 Patients With Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir in the Phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 Studies
|
|
|
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Christophe Hezode,1 Nancy Reau,2 Evguenia S. Svarovskaia,3 Brian P. Doehle,3 Krishna Chodavarapu,3 Hadas Dvory-Sobol,3 John McNally,3 Anu Osinusi,3 Diana M. Brainard,3 Michael D. Miller,3 Hongmei Mo,3 Stuart K. Roberts,4 Jacqueline G. O'Leary5
1Universite Paris-Est Creteil Val de Marne, Creteil, France; 2Rush University Medical Center, Chicago, Illinois, USA; 3Gilead Sciences, Inc., Foster City, California, USA; 4Alfred Health and Monash University, Melbourne, Victoria, Australia; 5Baylor University Medical Center at Dallas, Texas, USA
![EASL1](../images/041516/041516-9/EASL1.gif)
![EASL2](../images/041516/041516-9/EASL2.gif)
![EASL3](../images/041516/041516-9/EASL3.gif)
![EASL4](../images/041516/041516-9/EASL4.gif)
![EASL5](../images/041516/041516-9/EASL5.gif)
![EASL6](../images/041516/041516-9/EASL6.gif)
![EASL7](../images/041516/041516-9/EASL7.gif)
![EASL8](../images/041516/041516-9/EASL8.gif)
![EASL9](../images/041516/041516-9/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|